Pharmaceutical giant Novo Nordisk working on developing glucose responsive insulins.
A graduate who co-founded a company while studying at university could become a multi-millionaire after it was sold in a deal potentially worth £623m.
Dr Harry Destecroix, 31, co-founded Ziylo while studying for his PhD at the University of Bristol four years ago.
It created a new technology which can be developed to treat diabetes more effectively.
Pharmaceutical giant Novo Nordisk’s purchase means it now has full rights to develop glucose responsive insulins.